| Trial ID: | L4224 |
| Source ID: | NCT03604224
|
| Associated Drug: |
Canagliflozin 300 Mg
|
| Title: |
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Canagliflozin 300 mg
|
| Outcome Measures: |
Primary: Change From Baseline in Mean Hemoglobin A1c (HbA1c), Change in mean HbA1c from baseline to 12 weeks will be determined. HbA1c refers to glycated haemoglobin (A1c), which identifies average plasma glucose concentration., Baseline up to 12 weeks|Change From Baseline in Mean Weight, Change in mean body weight from baseline to 12 weeks will be determined., Baseline up to 12 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Johnson & Johnson Private Limited
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
178
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2018-09-05
|
| Completion Date: |
2019-07-01
|
| Results First Posted: |
|
| Last Update Posted: |
2020-08-19
|
| Locations: |
Diacon Hospital, Bangalore, 560010, India|Dr. A. Ramachandran's Diabetes Hospitals, Chennai, 600032, India|Apollo Hospitals, Kolkata, 700054, India
|
| URL: |
https://clinicaltrials.gov/show/NCT03604224
|
